Breast cancer can develop for several reasons, and hormones play an important role in many cases. For people diagnosed with hormone receptor-positive (HR-positive) breast cancer, oestrogen can influence how cancer cells grow and multiply. Understanding this connection can help patients make sense of their diagnosis and the treatments recommended by their healthcare team.
Table Of Content
Treatments for HR-positive breast cancer often focus on blocking the effects of oestrogen or reducing the amount produced by the body. However, the right approach depends on the type of cancer, its stage and the patient’s overall health.
Key Takeaways
|
An Overview of HR-Positive Breast Cancer
Hormone receptor-positive breast cancer develops when cancer cells have receptors for oestrogen, progesterone, or both. These receptors respond to hormonal signals that can influence cell growth and activity.
When cancer cells have oestrogen receptors, the cancer is described as oestrogen receptor-positive (ER-positive). If progesterone receptors are present, it is known as progesterone receptor-positive (PR-positive). Some tumours have both types of receptors.
Identifying these receptors is an important part of diagnosis because it helps doctors determine whether hormone therapy may be beneficial. Other factors, including the cancer’s stage, grade and HER2 status, also influence treatment planning.
The Role of Oestrogen in Cancer Growth
Oestrogen supports several normal bodily functions, including the development and maintenance of breast tissue. However, in HR-positive breast cancer, this hormone can also act as a signal that encourages cancer cells to multiply.
When oestrogen binds to its receptors, it activates processes that influence genes involved in cell growth and division. In hormone-sensitive tumours, these signals can contribute to cancer growth.
Oestrogen is not the only factor involved in breast cancer development. Changes in other cellular processes can also influence how the disease progresses. Nevertheless, blocking hormonal signals is an important treatment approach for many patients with HR-positive breast cancer.
Oestrogen levels also change with age. Right before menopause, the ovaries are the main source of this hormone. After menopause, production decreases, although smaller amounts continue to be produced in other tissues, including body fat. These remaining levels may still influence hormone-sensitive cancer cells.
Treatment and What to Keep in Mind
Hormone therapy, that is also known as endocrine therapy, is commonly used for HR-positive breast cancer. These medicines aim to interrupt the hormonal signals that encourage cancer cells to grow.
Tamoxifen blocks oestrogen receptors in breast cells, while aromatase inhibitors, such as letrozole and anastrozole, reduce oestrogen production in certain tissues. Some premenopausal patients may also receive treatment to suppress ovarian function.
The treatment plan depends on the patient’s menopausal status, cancer stage, medical history and previous treatment. Although hormone therapy can help control cancer growth and reduce the risk of recurrence in suitable patients, possible side effects should be discussed with the treating oncologist.
Important Considerations About Targeted Medicines
For few patients with advanced or metastatic HR-positive, HER2-negative breast cancer, doctors may recommend targeted medicines alongside hormone therapy.
Cancer cells depend on proteins that regulate cell division. Cyclin-dependent kinases 4 and 6 (CDK4/6) help control the cell cycle. Inhibiting these proteins can slow the multiplication of cancer cells.
Palbociclib is a CDK4/6 inhibitor used with appropriate hormone therapy for eligible patients. Paleno 125mg is a brand associated with palbociclib. The suitability of this medicine and the prescribed dose must be confirmed by an oncologist.
Treatment may require regular blood tests and monitoring because side effects can occur. Patients must follow their prescribed treatment plan and report any concerning symptoms to their healthcare team.
Preparing for Treatment
Before starting treatment, patients should understand the purpose of the recommended medicines, their potential side effects and the follow-up care required. Hormone receptor testing and HER2 results help doctors determine which treatments may be appropriate.
It can be helpful to ask the oncology team the following questions:
- What do my hormone receptor test results mean?
- Is hormone therapy suitable for my type of breast cancer?
- Could targeted treatment be appropriate for me?
- What side effects should I look out for?
- How will my response to treatment be monitored?
Discussing these concerns can help patients understand their options and make informed decisions with their healthcare team.
Conclusion
Oestrogen can encourage the growth of HR-positive breast cancer by activating receptors that influence cancer cell division. Hormone therapy aims to block these signals or reduce hormone production, while targeted medicines may help slow cancer cell multiplication in eligible patients.
Every patient’s situation is different, so treatment should be tailored to the cancer’s characteristics and individual medical needs. Speaking with an oncologist can help patients understand their diagnosis and the available treatment options.
Disclaimer: This article is intended for general informational purposes and should not replace professional medical advice. Consult a qualified healthcare professional before starting, changing or stopping any medicine.
